肾功能不全患者对纳多洛尔的消除情况。
Elimination of nadolol by patients with renal impairment.
作者信息
Herrera J, Vukovich R A, Griffith D L
出版信息
Br J Clin Pharmacol. 1979;7 Suppl 2(Suppl 2):227S-231S. doi: 10.1111/j.1365-2125.1979.tb04694.x.
Abstract
1 Nadolol excretion was studied in 24 patients with chronic renal failure. 2 The amount of nadolol excreted during the 120-h period after receiving the drug ranged from less than 1% in functionally anephric, patients up to 11.5% in patients with average creatinine clearance of 57.9 +/- 3.6 ml/min/1.73 m2. 3 Renal clearance of nadolol was found to correlate with creatinine clearance; nadolol elimination is retarded in patients with renal failure. 4 Nadolol serum half-life is prolonged in proportion to the remaining renal function. Therefore, dosage intervals in renal patients receiving nadolol should be adjusted to creatinine clearance. 5 Haemodialysis effectively reduced serum concentration of the drug; it may therefore be a useful therapy for drug intoxication.
摘要
对24例慢性肾衰竭患者的纳多洛尔排泄情况进行了研究。
给药后120小时内，无功能肾患者排出的纳多洛尔量不到1%，而肌酐清除率平均为57.9±3.6 ml/min/1.73 m2的患者排出量高达11.5%。
发现纳多洛尔的肾清除率与肌酐清除率相关；肾衰竭患者的纳多洛尔消除延迟。
纳多洛尔的血清半衰期与剩余肾功能成比例延长。因此，接受纳多洛尔治疗的肾病患者的给药间隔应根据肌酐清除率进行调整。
血液透析有效降低了药物的血清浓度；因此，它可能是治疗药物中毒的一种有效疗法。
相似文献
1
Elimination of nadolol by patients with renal impairment.肾功能不全患者对纳多洛尔的消除情况。
Br J Clin Pharmacol. 1979;7 Suppl 2(Suppl 2):227S-231S. doi: 10.1111/j.1365-2125.1979.tb04694.x.
2
Butofilolol pharmacokinetics in chronic renal insufficiency.
Int J Clin Pharmacol Res. 1984;4(3):165-73.
3
4
Nadolol in hypertensive patients maintained on long-term hemodialysis.
Am Heart J. 1984 Oct;108(4 Pt 2):1091-4. doi: 10.1016/0002-8703(84)90587-8.
5
Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.慢性肾衰竭患者和健康志愿者单次口服他林洛尔后的药代动力学及稳态药代动力学
Int J Clin Pharmacol Ther. 2001 Feb;39(2):61-6. doi: 10.5414/cpp39061.
6
Nadolol in human serum and breast milk.
Br J Clin Pharmacol. 1981 Sep;12(3):393-6. doi: 10.1111/j.1365-2125.1981.tb01232.x.
7
Pharmacokinetics of carteolol in relation to renal function.卡替洛尔的药代动力学与肾功能的关系。
Eur J Clin Pharmacol. 1985;29(4):461-5. doi: 10.1007/BF00613462.
8
[Pharmacology and clinical pharmacokinetics of nadolol].纳多洛尔的药理学与临床药代动力学
Pol Tyg Lek. 1981 Sep 28;36(39):1521-4.
9
Pharmacokinetics of nadolol in healthy subjects.纳多洛尔在健康受试者中的药代动力学。
Eur J Clin Pharmacol. 1984;26(1):125-7. doi: 10.1007/BF00546720.
10
A comparison of propranolol and nadolol pharmacokinetics and clinical effects in thyrotoxicosis.
Am Heart J. 1984 Oct;108(4 Pt 2):1160-7. doi: 10.1016/0002-8703(84)90601-x.
引用本文的文献
1
A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia.肾病成人及室上性心动过速儿科患者中纳多洛尔的综合生理学药代动力学模型。
Pharmaceuticals (Basel). 2024 Feb 19;17(2):265. doi: 10.3390/ph17020265.
2
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.体外治疗β-肾上腺素能拮抗剂中毒：EXTRIP 工作组的系统评价和建议。
Crit Care. 2021 Jun 10;25(1):201. doi: 10.1186/s13054-021-03585-7.
3
Cardiovascular drug therapy in the elderly: theoretical and practical considerations.老年人的心血管药物治疗：理论与实践考量
Drugs Aging. 2003;20(6):445-63. doi: 10.2165/00002512-200320060-00004.
4
Bioequivalence of a highly variable drug: an experience with nadolol.高变异药物的生物等效性：纳多洛尔的经验
Pharm Res. 1996 Jul;13(7):1109-15. doi: 10.1023/a:1016031313065.
5
The new beta-adrenergic antagonists.新型β-肾上腺素能拮抗剂
Can Anaesth Soc J. 1984 Jul;31(4):430-3. doi: 10.1007/BF03015419.
6
Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.药物动力学特性的差异：对肾衰竭患者选用特定药物的意义，特别强调抗生素和β-肾上腺素能受体阻滞剂。
Clin Pharmacokinet. 1980 Sep-Oct;5(5):441-64. doi: 10.2165/00003088-198005050-00003.
7
Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.纳多洛尔：对其药理学特性及在高血压和心绞痛治疗中的疗效综述。
Drugs. 1980 Jul;20(1):1-23. doi: 10.2165/00003495-198020010-00001.
8
Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.β-肾上腺素能受体拮抗剂的临床药代动力学。最新进展。
Clin Pharmacokinet. 1987 May;12(5):305-20. doi: 10.2165/00003088-198712050-00001.
9
Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.老年患者的抗高血压治疗。临床药代动力学考量。
Drugs Aging. 1991 May;1(3):194-211. doi: 10.2165/00002512-199101030-00004.
本文引用的文献
1
Studies on the epidemiology of adverse drug reactions. V. Clinical factors influencing susceptibility.药物不良反应的流行病学研究。V. 影响易感性的临床因素。
Ann Intern Med. 1966 Oct;65(4):629-40. doi: 10.7326/0003-4819-65-4-629.
2
Drug dosage in patients with impaired renal function.肾功能受损患者的药物剂量。
Postgrad Med J. 1970 Oct:Suppl:32-5.
3
Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.高血压患者在肾功能正常和受损情况下吲哚洛尔的药代动力学及肝脏摄取率
J Clin Pharmacol. 1977 Aug-Sep;17(8-9):501-8. doi: 10.1002/j.1552-4604.1977.tb05643.x.
4
Elimination of furosemide in healthy subjects and in those with renal failure.
Clin Pharmacol Ther. 1977 Jul;22(1):70-8. doi: 10.1002/cpt197722170.
5
Pharmacokinetics and hemodialyzability of cefazolin in uremic patients.
Clin Pharmacol Ther. 1976 Jun;19(6):825-9. doi: 10.1002/cpt1976196825.
6
Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression.纳多洛尔（SQ 11725）的药理学，一种缺乏直接心肌抑制作用的β肾上腺素能拮抗剂。
Eur J Pharmacol. 1975 Sep-Oct;33(2):371-82. doi: 10.1016/0014-2999(75)90182-x.
7
Comparison of the new beta-adrenoceptor antagonist, nadolol, and propranolol in the treatment of angina pectoris.
Curr Med Res Opin. 1978;5(5):388-93. doi: 10.1185/03007997809111903.
8
Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertension.
Curr Med Res Opin. 1978;5(5):383-7. doi: 10.1185/03007997809111902.
9
Fluorometric determination of nadolol in human serum and urine.荧光法测定人血清和尿液中的纳多洛尔。
J Pharm Sci. 1977 Aug;66(8):1168-72. doi: 10.1002/jps.2600660831.
10
Metabolic studies in patients with nadolol: oral and intravenous administration.纳多洛尔患者的代谢研究：口服与静脉给药
J Clin Pharmacol. 1977 May-Jun;17(5-6):300-7. doi: 10.1002/j.1552-4604.1977.tb04609.x.
Zotero 插件